Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data

1 Jan 2015

Abstract excerpt

Anaplastic lymphoma kinase(ALK) rearrangement is one of the oncogenes in non-small cell lung cancer (NSCLC) identified in 2007. The PROFILE trials demonstrated that patients with ALK-rearranged NSCLC can be successfully treated with crizotinib, and that crizotinib is superior to chemotherapy in both first- and second-line settings. Furthermore, next-generation ALK inhibitors, such as alectinib and ceritinib, have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26045026
DOI: 10.1159/000430852

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataPMID 26045026Read ↗

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.Semantic proximity Read ↗

The battle against ALK resistance: successes and setbacksSemantic proximity Read ↗

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancerSemantic proximity Read ↗

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung CancerSemantic proximity Read ↗

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Semantic proximity Read ↗

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistanceSemantic proximity Read ↗

Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung CancerSemantic proximity Read ↗

Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.Semantic proximity Read ↗

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.Semantic proximity Read ↗

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.